Danaher Reports Third Quarter 2026 Results
Danaher reported Q3 2026 revenue of $6.6 billion, up 8.5% year-over-year, with net earnings of $1.2 billion ($1.71 diluted EPS) up 34.5% YoY. Adjusted diluted EPS grew 11.5% to $2.11, and management cited better-than-expected revenue, earnings and cash flow with improving end-market trends. Core revenue grew 3.0%, or 5.5% excluding respiratory testing, with Diagnostics GAAP sales up 17.0%. The company raised full-year adjusted EPS guidance to $8.57-$8.62 from $8.45-$8.60 and guided Q4 core revenue ex-respiratory growth of 4.0-5.0% with a ~29.5% adjusted operating margin.
Key figures
- Eps
- 1.71
- Revenue
- $6.6 billion
- Guidance
- FY2026 adjusted diluted EPS raised to $8.57-$8.62 from $8.45-$8.60; Q4 core revenue ex-respiratory growth of 4.0-5.0%, core revenue growth ~3.0%; Q4 adjusted operating profit margin ~29.5%
- Revenue Yoy
- 8.5%
- Adjusted eps
- 2.11
- Gross profit
- 3837000000
- Net earnings
- $1.2 billion
- Free cash flow
- $1.6 billion
- Adjusted eps yoy
- 11.5%
- Net earnings yoy
- 34.5%
- Operating income
- 1245000000
- Free cash flow yoy
- ~19.0%
- Core revenue growth
- 3.0%
- Operating cash flow
- $1.9 billion
- Core revenue growth ex respiratory
- 5.5%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.